Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs

Edward P Armstrong, Grant H. Skrepnek, Medha Sasane, Susan M. Snodgrass, Samir K. Ballas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: This retrospective study evaluated iron chelating therapy (ICT) discontinuation and costs in Sickle cell disease (SCD) Medicaid recipients using healthcare claims from 2006-2010. Methods: Patients with ≥1 SCD diagnosis claim, ≥2 claims for deferoxamine (DFO) or deferosirox (DFX), and continuous enrollment ≥6 months prior to and 18 months following ICT initiation were included. Outcomes included treatment discontinuation, persistence (i.e., refill gaps ≥6 weeks), and total healthcare costs. Results: The average age among 404 SCD patients meeting study inclusion criteria was 18.7 (±11.0) years, with 45.8% being males and 66.7% being Blacks. Switches or combinations from DFO at index occurred in 124 (74.7%) patients compared to 10 (4.2%) with DFX at index. The Cox regression model that assessed long-term medication persistence indicated a 1.30-times higher likelihood of treatment discontinuation with DFO compared to DFX (95% CI: 1.06-1.61). Some 19.7% of patient remained on DFX relative to 4.8% on DFO. Both inpatient and total costs were similar in DFX and DFO treatment groups. Following 1 year of treatment, 37.4% remained on DFX compared to 15.7% on DFO. Meaningful differences in treatment discontinuation between the two treatment groups did not occur until 220+ days during the study period. At 18-months, treatment discontinuation rates were high in both groups; 95% for DFO and 80% for DFX. Conclusion: This study of SCD Medicaid patients found more therapeutic switches from DFO to DFX and a higher medication persistency rate with DFX than DFO. The conclusions are limited by the study's retrospective nature, which depends on multivariate statistics to account for patient heterogeneity and risk factors.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalJournal of Medical Economics
Volume16
Issue number1
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Chelation Therapy
Deferoxamine
Medicaid
Sickle Cell Anemia
Iron
Costs and Cost Analysis
Therapeutics
Retrospective Studies
Medication Adherence
Proportional Hazards Models
Health Care Costs
Inpatients
Delivery of Health Care

Keywords

  • Iron chelation therapy
  • Medication adherence
  • Sickle cell disease

ASJC Scopus subject areas

  • Health Policy

Cite this

Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. / Armstrong, Edward P; Skrepnek, Grant H.; Sasane, Medha; Snodgrass, Susan M.; Ballas, Samir K.

In: Journal of Medical Economics, Vol. 16, No. 1, 2013, p. 10-18.

Research output: Contribution to journalArticle

@article{271ad58f703a4db3ace13b715b6f652a,
title = "Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs",
abstract = "Objective: This retrospective study evaluated iron chelating therapy (ICT) discontinuation and costs in Sickle cell disease (SCD) Medicaid recipients using healthcare claims from 2006-2010. Methods: Patients with ≥1 SCD diagnosis claim, ≥2 claims for deferoxamine (DFO) or deferosirox (DFX), and continuous enrollment ≥6 months prior to and 18 months following ICT initiation were included. Outcomes included treatment discontinuation, persistence (i.e., refill gaps ≥6 weeks), and total healthcare costs. Results: The average age among 404 SCD patients meeting study inclusion criteria was 18.7 (±11.0) years, with 45.8{\%} being males and 66.7{\%} being Blacks. Switches or combinations from DFO at index occurred in 124 (74.7{\%}) patients compared to 10 (4.2{\%}) with DFX at index. The Cox regression model that assessed long-term medication persistence indicated a 1.30-times higher likelihood of treatment discontinuation with DFO compared to DFX (95{\%} CI: 1.06-1.61). Some 19.7{\%} of patient remained on DFX relative to 4.8{\%} on DFO. Both inpatient and total costs were similar in DFX and DFO treatment groups. Following 1 year of treatment, 37.4{\%} remained on DFX compared to 15.7{\%} on DFO. Meaningful differences in treatment discontinuation between the two treatment groups did not occur until 220+ days during the study period. At 18-months, treatment discontinuation rates were high in both groups; 95{\%} for DFO and 80{\%} for DFX. Conclusion: This study of SCD Medicaid patients found more therapeutic switches from DFO to DFX and a higher medication persistency rate with DFX than DFO. The conclusions are limited by the study's retrospective nature, which depends on multivariate statistics to account for patient heterogeneity and risk factors.",
keywords = "Iron chelation therapy, Medication adherence, Sickle cell disease",
author = "Armstrong, {Edward P} and Skrepnek, {Grant H.} and Medha Sasane and Snodgrass, {Susan M.} and Ballas, {Samir K.}",
year = "2013",
doi = "10.3111/13696998.2012.723081",
language = "English (US)",
volume = "16",
pages = "10--18",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs

AU - Armstrong, Edward P

AU - Skrepnek, Grant H.

AU - Sasane, Medha

AU - Snodgrass, Susan M.

AU - Ballas, Samir K.

PY - 2013

Y1 - 2013

N2 - Objective: This retrospective study evaluated iron chelating therapy (ICT) discontinuation and costs in Sickle cell disease (SCD) Medicaid recipients using healthcare claims from 2006-2010. Methods: Patients with ≥1 SCD diagnosis claim, ≥2 claims for deferoxamine (DFO) or deferosirox (DFX), and continuous enrollment ≥6 months prior to and 18 months following ICT initiation were included. Outcomes included treatment discontinuation, persistence (i.e., refill gaps ≥6 weeks), and total healthcare costs. Results: The average age among 404 SCD patients meeting study inclusion criteria was 18.7 (±11.0) years, with 45.8% being males and 66.7% being Blacks. Switches or combinations from DFO at index occurred in 124 (74.7%) patients compared to 10 (4.2%) with DFX at index. The Cox regression model that assessed long-term medication persistence indicated a 1.30-times higher likelihood of treatment discontinuation with DFO compared to DFX (95% CI: 1.06-1.61). Some 19.7% of patient remained on DFX relative to 4.8% on DFO. Both inpatient and total costs were similar in DFX and DFO treatment groups. Following 1 year of treatment, 37.4% remained on DFX compared to 15.7% on DFO. Meaningful differences in treatment discontinuation between the two treatment groups did not occur until 220+ days during the study period. At 18-months, treatment discontinuation rates were high in both groups; 95% for DFO and 80% for DFX. Conclusion: This study of SCD Medicaid patients found more therapeutic switches from DFO to DFX and a higher medication persistency rate with DFX than DFO. The conclusions are limited by the study's retrospective nature, which depends on multivariate statistics to account for patient heterogeneity and risk factors.

AB - Objective: This retrospective study evaluated iron chelating therapy (ICT) discontinuation and costs in Sickle cell disease (SCD) Medicaid recipients using healthcare claims from 2006-2010. Methods: Patients with ≥1 SCD diagnosis claim, ≥2 claims for deferoxamine (DFO) or deferosirox (DFX), and continuous enrollment ≥6 months prior to and 18 months following ICT initiation were included. Outcomes included treatment discontinuation, persistence (i.e., refill gaps ≥6 weeks), and total healthcare costs. Results: The average age among 404 SCD patients meeting study inclusion criteria was 18.7 (±11.0) years, with 45.8% being males and 66.7% being Blacks. Switches or combinations from DFO at index occurred in 124 (74.7%) patients compared to 10 (4.2%) with DFX at index. The Cox regression model that assessed long-term medication persistence indicated a 1.30-times higher likelihood of treatment discontinuation with DFO compared to DFX (95% CI: 1.06-1.61). Some 19.7% of patient remained on DFX relative to 4.8% on DFO. Both inpatient and total costs were similar in DFX and DFO treatment groups. Following 1 year of treatment, 37.4% remained on DFX compared to 15.7% on DFO. Meaningful differences in treatment discontinuation between the two treatment groups did not occur until 220+ days during the study period. At 18-months, treatment discontinuation rates were high in both groups; 95% for DFO and 80% for DFX. Conclusion: This study of SCD Medicaid patients found more therapeutic switches from DFO to DFX and a higher medication persistency rate with DFX than DFO. The conclusions are limited by the study's retrospective nature, which depends on multivariate statistics to account for patient heterogeneity and risk factors.

KW - Iron chelation therapy

KW - Medication adherence

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84870916333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870916333&partnerID=8YFLogxK

U2 - 10.3111/13696998.2012.723081

DO - 10.3111/13696998.2012.723081

M3 - Article

C2 - 22947171

AN - SCOPUS:84870916333

VL - 16

SP - 10

EP - 18

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 1

ER -